Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Daniel J. DeAngelo, MD, PhD, on the significance of the updated data for gilteritinib in AML

Dr. DeAngelo, Chief, Division of Leukemia, Institute Physician, Professor of Medicine, Harvard Medical School, explains the significance of the updated survival data for gilteritinib in acute myeloid leukemia (AML)

Tags: ASCO Conference CoverageLeukemia (includes ALL, AML, APL, CLL, CML, MDS, Myeloproliferative Disorders, Myelofibrosis)

Published: 03 June 2019

Recent Videos

video

Amer Zeidan, MBBS, speculates on the role of immune checkpoint blockades in myeloid malignancies

Dr. Zeidan, Associate Professor of Hematology, Yale School of Medicine, Yale Cancer Center, speculates on the role of immune checkpoint ...

video

Tanya Siddiqi, MD, elaborates on outcomes from the Phase 2 CAPTIVATE study presented at ASH '19

Dr. Siddiqi, Director, CLL Program, Toni Stephenson Lymphoma Center, Associate Clinical Professor, Department of Hematology, City of Hope, elaborates on ...

video

Tanya Siddiqi, MD, considers whether data supports the use of CAR-T cell therapy in lymphoma

Dr. Siddiqi, Director, CLL Program, Toni Stephenson Lymphoma Center, Associate Clinical Professor, Department of Hematology, City of Hope, considers whether ...

video

Tanya Siddiqi, MD, regarding the Transcend-NHL data investigating CAR-T cell therapy in CLL

Dr. Siddiqi, Director, CLL Program, Toni Stephenson Lymphoma Center, Associate Clinical Professor, Department of Hematology, City of Hope, offers impressions ...

video

Gwen Nichols, MD, regarding the collaboration between the Leukemia and Lymphoma Society and ASH

Dr. Nichols, Chief Medical Officer-Physician, Scientific Research Portfolio, Patient Access Services, Policy and Advocacy Initiatives, Leukemia and Lymphoma Society, tells ...

video

Gwen Nichols, MD, on what the Leukemia and Lymphoma Society is doing to help educate members

Dr. Nichols, Chief Medical Officer-Physician, Scientific Research Portfolio, Patient Access Services, Policy and Advocacy Initiatives, Leukemia and Lymphoma Society, elaborates ...

video

Gwen Nichols, MD, offers opinion on the most exciting progress in hematological malignancies

Dr. Nichols, Chief Medical Officer-Physician, Scientific Research Portfolio, Patient Access Services, Policy and Advocacy Initiatives, Leukemia and Lymphoma Society, offers ...

video

Gwen Nichols, MD, provides opinion on the most promising clinical presentations from ASH 2019

Dr. Nichols, Chief Medical Officer-Physician, Scientific Research Portfolio, Patient Access Services, Policy and Advocacy Initiatives, Leukemia and Lymphoma Society, provides ...

video

Robert Rifkin, MD, FACP, regarding the role of proteasome inhibitors in maintenance therapy for MM

Dr. Rifkin, Attending Physician, Department of Cellular Therapy, Presbyterian/St. Luke’s Medical Center, regarding the role of proteasome inhibitors in maintenance ...

video

Richard Stone, MD, describes the landscape of mutations and targeted therapy in AML

Dr. Stone, Physician, Hematologic Oncology, Internal Medicine, Dana-Farber Cancer Institute, describes the landscape of mutations and targeted therapy in acute ...

Related Videos

video-image

Amer Zeidan, MBBS, speculates on the role of immune checkpoint blockades in myeloid malignancies

video-image

Richard Stone, MD, shares thoughts on current treatment strategies for elderly AML patients

video-image

Gwen Nichols, MD, offers opinion on the most exciting progress in hematological malignancies

video-image

Nikhil Munshi, MD, on the association between MRD and survival outcomes in multiple myeloma

video-image

Gwen Nichols, MD, on what the Leukemia and Lymphoma Society is doing to help educate members

video-image

Richard Stone, MD, offers his impression of the landscape for FLT3 inhibition in AML

video-image

Gwen Nichols, MD, regarding the collaboration between the Leukemia and Lymphoma Society and ASH

video-image

Nikhil Munshi, MD, tells us about the outcomes of the CARTITUDE-1 study from ASH 2019

video-image

Tanya Siddiqi, MD, regarding the Transcend-NHL data investigating CAR-T cell therapy in CLL

video-image

Richard Stone, MD, elaborates on prognostic factors and the relationship to outcomes in AML

video-image

Tanya Siddiqi, MD, considers whether data supports the use of CAR-T cell therapy in lymphoma

video-image

Frederick Locke, MD, regarding the clinical evidence supporting CAR-T cell therapies in MM

video-image

Tanya Siddiqi, MD, elaborates on outcomes from the Phase 2 CAPTIVATE study presented at ASH '19

video-image

Richard Stone, MD, provides opinion on whether all AML patients should be tested for FLT3 mutations

video-image

Frederick Locke, MD, provides his impression of the Transcend-NHL study from ASH 2019

video-image

Peter M. Voorhees, MD, shares the current thinking regarding treatment algorithms in MM

video-image

Richard Stone, MD, describes the landscape of mutations and targeted therapy in AML

video-image

Richard Stone, MD, on how oral HMA agents may impact the treatment landscape in myeloid malignancies

video-image

Robert Rifkin, MD, FACP, regarding the role of proteasome inhibitors in maintenance therapy for MM

video-image

Nikhil Munshi, MD, considers recent data investigating the bi-specific CAR-T cell therapy